Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of TSR-022 (Cobolimab) in Combination With TSR-042 (Dostarlimab) for the Treatment of Advanced Hepatocellular Carcinoma

NCT03680508 is registered in ClinicalTrials.gov with University of Hawaii as lead sponsor.

NCT NCT03680508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03680508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of TSR-022 (Cobolimab) in Combination With TSR-042 (Dostarlimab) for the Treatment of Advanced Hepatocellular Carcinoma
Lead sponsor
University of Hawaii
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 19, 2019
Completion date
October 31, 2027
Enrollment
42 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adult primary liver cancer, advanced adult primary liver cancer, localized unresectable adult primary liver cancer